Munich Reinsurance Co Stock Corp in Munich Takes $5.80 Million Position in Insulet Corporation $PODD

Key Points

• Munich Re acquired a new stake in Insulet, buying 20,218 shares in Q4 valued at about $5.80 million.
• Insulet beat Q1 expectations, reporting EPS of $1.55 versus $1.48 expected and revenue of $783.8M, up 31.2% year‑over‑year.
• Director Michael R. Minogue bought 2,030 shares at $246.23, raising his holdings to 17,483 shares (a 13.14% increase), indicating insider buying.

Munich Reinsurance Co Stock Corp in Munich acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 20,218 shares of the medical instruments supplier's stock, valued at approximately $5,803,000.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC increased its holdings in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 72 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier's stock valued at $40,000 after acquiring an additional 43 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in shares of Insulet in the 3rd quarter valued at about $49,000. Quent Capital LLC purchased a new position in shares of Insulet in the 3rd quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Insulet in the 2nd quarter valued at about $51,000.

Insiders Place Their Bets

In related news, Director Michael R. Minogue acquired 2,030 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares of the company's stock, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.39% of the company's stock.

Insulet Stock Down 1.4%

Shares of NASDAQ PODD opened at $189.56 on Friday. The stock has a market cap of $13.13 billion, a PE ratio of 54.16, a price-to-earnings-growth ratio of 1.15 and a beta of 1.47. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. Insulet Corporation has a 52-week low of $186.25 and a 52-week high of $354.88. The business has a 50-day moving average price of $222.23 and a 200 day moving average price of $271.72.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping analysts' consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company had revenue of $783.80 million during the quarter, compared to analysts' expectations of $768.31 million. During the same period last year, the firm earned $1.15 EPS. The firm's revenue for the quarter was up 31.2% on a year-over-year basis. Equities research analysts forecast that Insulet Corporation will post 6.16 earnings per share for the current year.

Analyst Ratings Changes

PODD has been the topic of a number of recent analyst reports. Zacks Research downgraded Insulet from a "strong-buy" rating to a "hold" rating in a report on Monday, January 5th. Raymond James Financial decreased their target price on Insulet from $385.00 to $355.00 and set an "outperform" rating for the company in a research report on Thursday, February 19th. JPMorgan Chase & Co. decreased their target price on Insulet from $415.00 to $340.00 and set an "overweight" rating for the company in a research report on Thursday, February 19th. The Goldman Sachs Group decreased their target price on Insulet from $326.00 to $277.00 and set a "buy" rating for the company in a research report on Wednesday, April 8th. Finally, Barclays reissued an "underweight" rating and issued a $286.00 target price on shares of Insulet in a research report on Thursday, February 19th. Eighteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $327.24.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.